Table 2.
Multi-class drug resistance and cases of protease inhibitor (PI) and INSTI resistance amongst all participants
ID | ART class | No. of classes | ART status | |||
---|---|---|---|---|---|---|
NRTI | NNRTI | PI | INSTI | |||
1 | – | – | – | Yes | 1 | ART-Experienced |
2 | – | – | Yes | – | 1 | ART-Experienced |
3 | – | – | Yes | – | 1 | ART-Experienced |
4 | – | – | Yes | – | 1 | ART-Experienced |
5 | – | Yes | Yes | – | 2 | ART-Experienced |
6 | – | Yes | Yes | – | 2 | ART-Experienced |
7 | – | Yes | Yes | – | 2 | ART-Experienced |
8 | Yes | Yes | Yes | – | 3 | ART-Experienced |
9 | Yes | Yes | Yes | – | 3 | ART-Experienced |
10 | Yes | Yes | Yes | – | 3 | ART-Experienced |
11 | – | – | Yes | – | 1 | ART-Naïve |
12 | – | – | Yes | – | 1 | ART-Naïve |
13 | – | – | Yes | – | 1 | ART-Naïve |
14 | – | – | Yes | – | 1 | ART-Naïve |
15 | – | Yes | Yes | – | 2 | ART-Naïve |
Three individuals exhibited three-class resistance. Seven showed PI resistance only. None of these participants existed in a linkage cluster.
INSTI integrase strand transfer inhibitors, NNRTI non-nucleoside reverse transcriptase inhibitors, NRTI nucleoside/nucleotide reverse transcriptase inhibitors, PI protease inhibitors.